Pomerantz Law Firm Investigates ARS Pharmaceuticals Over Investor Claims
Pomerantz LLP is investigating ARS Pharmaceuticals, Inc. and its officers for alleged securities fraud following disclosure issues regarding its product neffy®.
Pomerantz LLP has launched an investigation into ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) concerning allegations of securities fraud or other unlawful business practices. The inquiry follows a June 24, 2026, press release from ARS Pharmaceuticals stating that its product, neffy® (epinephrine nasal spray), failed to secure commercial insurance coverage.
Following this announcement, ARS Pharmaceuticals' stock price declined by $2.52 per share, a drop of 23.91%, to close at $8.02 on June 25, 2026. The law firm is advising investors with relevant information to contact them.
The investigation aims to determine if ARS Pharmaceuticals and certain of its officers and/or directors engaged in fraudulent activities or misconduct. Pomerantz LLP, with a history in class action litigation, is handling the case.
This development adds scrutiny to ARS Pharmaceuticals after the critical news about its product's insurance coverage. Investors impacted by the stock's subsequent fall are encouraged to come forward with information.